Dupixent is back on top as the pharma brand that took home the most TV impressions in May, according to data released by iSpot.tv on Thursday morning. Regeneron and Sanofi’s eczema and asthma ...
After several months, inflammatory disease medication Dupixent has finally reclaimed its spot atop the rankings for over-the-counter (OTC) and Rx brand marketing on TV. The Regeneron and Sanofi brand, ...
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...
Apogee Therapeutics, Inc. achieved positive interim results from phase 1b study using APG808 for the treatment of patients with Asthma. Interim 16-week data from the phase 2 APEX study using APG777 ...
Hosted on MSN
Sanofi stock slides on Dupixent successor AD trial
Sanofi’s stock dropped in the wake of data from its Phase III trial of atopic dermatitis (AD) candidate amlitelimab, which had been touted as a potential successor to Dupixent. While the Phase III ...
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback